, Singapore
268 views
Photo by Pixabay via Pexels

Hyphens Pharma profit dives 44% in 2025 despite record 40.7% gross margins

Net profit fell to $6.1m in 2025 as higher costs and inventory write-offs offset proprietary brand growth.

Hyphens Pharma International Limited posted a net profit of $6.1m for the year ended 31 December 2025, down 44% from $10.9m in FY2024.

Basic earnings per share fell to 1.89 Singapore cents from 3.30 cents a year earlier, according to the company’s FY2025 financial statements.

Revenue declined 9.2% to $177.4m, as lower sales from the Pharmaceutical and Medical Aesthetics segment and the Digital Platform and e-Pharmacy segment outweighed a 33.1% increase in Proprietary Brands revenue to $36.7m.

Gross profit rose 3.8% to $72.2m, with the gross margin improving to 40.7% from 35.6%, reflecting higher-margin products in the company’s portfolio.

Hyphens Pharma said that despite challenges including foreign exchange volatility, elevated operating costs, and inventory write-offs, its diversified business model across three segments, namely Pharmaceutical and Medical Aesthetics, Proprietary Brands, and Digital Platform and e-Pharmacy, provides resilience.

Join Singapore Business Review community

Follow the link for more news on

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.